Core Viewpoint - Allegro MicroSystems, Inc. (ALGM) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook driven by an upward trend in earnings estimates [1][4][11] Earnings Estimates and Revisions - The Zacks Consensus Estimate for Allegro MicroSystems is projected at $0.53 per share for the fiscal year ending March 2026, showing no year-over-year change [9] - Over the past three months, the Zacks Consensus Estimate for Allegro MicroSystems has increased by 21.8% [9] Zacks Rating System - The Zacks rating system is based solely on a company's changing earnings picture, which is a key determinant of stock ratings [2][3] - The system classifies stocks into five groups, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8] - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [10][11] Market Implications - Rising earnings estimates and the Zacks rating upgrade suggest an improvement in Allegro MicroSystems' underlying business, which could lead to higher stock prices [6][4] - The correlation between earnings estimate revisions and near-term stock movements highlights the importance of tracking these revisions for investment decisions [7][5]

Core Viewpoint - Forrester Research (FORR) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based solely on a company's changing earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Forrester Research reflects an improvement in its earnings outlook, which is expected to lead to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [5]. - Forrester Research's rising earnings estimates and the subsequent rating upgrade suggest an enhancement in the company's underlying business, likely resulting in higher stock prices as investors respond positively to this trend [6]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [8]. - The upgrade of Forrester Research to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][11]. Current Earnings Estimates for Forrester Research - Forrester Research is projected to earn $1.27 per share for the fiscal year ending December 2025, with no year-over-year change, but the Zacks Consensus Estimate has increased by 1.8% over the past three months [9].

Core Viewpoint - MPLX LP has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Recent Performance and Outlook - For the fiscal year ending December 2025, MPLX LP is expected to earn $4.43 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 1% over the past three months [8]. - The upgrade to Zacks Rank 2 places MPLX LP in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The system maintains a balanced distribution of ratings, ensuring that only the top 5% of stocks receive a "Strong Buy" rating, while the next 15% receive a "Buy" rating [9].

Core Viewpoint - Aviva (AVVIY) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which are crucial for stock price movements [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the importance of earnings estimate revisions, which have a strong correlation with near-term stock price movements [4][6]. - For Aviva, the Zacks Consensus Estimate for earnings per share (EPS) for the fiscal year ending December 2025 is projected at $1.38, showing no year-over-year change, but estimates have increased by 4.2% over the past three months [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - Aviva's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Core Viewpoint - Strawberry Fields REIT, Inc. has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the importance of earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [4][6]. - For Strawberry Fields REIT, the Zacks Consensus Estimate for earnings per share for the fiscal year ending December 2025 is projected at $1.27, with no year-over-year change [8]. - Over the past three months, analysts have raised their earnings estimates for Strawberry Fields REIT by 5.4% [8]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [9][10].

Core Viewpoint - Investar (ISTR) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in stock price movements [4]. Recent Performance and Outlook - For the fiscal year ending December 2025, Investar is expected to earn $1.99 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 21% over the past three months [8]. - The upgrade to Zacks Rank 2 positions Investar in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimate revisions, with a proven track record of generating significant returns, particularly for Zacks Rank 1 stocks [7][9]. - The system maintains a balanced distribution of ratings, ensuring that only the top 20% of stocks receive favorable ratings based on their earnings estimate revisions [9][10].

Core Viewpoint - MasterCard has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, indicating a positive earnings outlook that could lead to increased stock price [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, which is a significant factor influencing stock prices [1][4]. - Changes in earnings estimates are strongly correlated with near-term stock price movements, making the Zacks rating system valuable for investors [2][4]. Institutional Investor Influence - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, and their investment actions based on these estimates can lead to stock price movements [4]. MasterCard's Earnings Outlook - MasterCard is expected to earn $15.99 per share for the fiscal year ending December 2025, with no year-over-year change, but the Zacks Consensus Estimate has increased by 0.7% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - MasterCard's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

BioCryst Pharmaceuticals (BCRX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the syst ...

Core Viewpoint - ResMed (RMD) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Group 1: Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in a company's earnings picture, specifically tracking EPS estimates from sell-side analysts [1][2]. - A strong correlation exists between earnings estimate revisions and near-term stock price movements, making the Zacks rating system valuable for investors [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Group 2: ResMed's Earnings Outlook - ResMed is projected to earn $9.48 per share for the fiscal year ending June 2025, indicating no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for ResMed has increased by 0.2%, reflecting a positive outlook for the company's earnings [8]. Group 3: Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 20% of Zacks-covered stocks receive a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - ResMed's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for higher stock movement in the near term [10].

Core Viewpoint - Zymeworks Inc. (ZYME) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The recent upgrade for Zymeworks reflects an improvement in the company's underlying business, suggesting that investors may push the stock price higher [5]. - For the fiscal year ending December 2025, Zymeworks is expected to earn -$1.64 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 5.8% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zymeworks now positioned in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns [10]. - The Zacks Rank 2 rating places Zymeworks among stocks with superior earnings estimate revisions, suggesting a likelihood of upward price movement in the near term [10].